Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 156

1.

Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis.

Tognin S, Catalan A, Modinos G, Kempton MJ, Bilbao A, Nelson B, Pantelis C, Riecher-Rössler A, Bressan R, Barrantes-Vidal N, Krebs MO, Nordentoft M, Ruhrmann S, Sachs G, Rutten BPF, van Os J, de Haan L, van der Gaag M; EU-GEI High Risk Study, McGuire P, Valmaggia LR.

Schizophr Bull. 2020 Feb 21. pii: sbz128. doi: 10.1093/schbul/sbz128. [Epub ahead of print]

PMID:
32080743
2.

Reliability and correlation of mixture cell correction in methylomic and transcriptomic blood data.

Chaumette B, Kebir O, Dion PA, Rouleau GA, Krebs MO.

BMC Res Notes. 2020 Feb 12;13(1):74. doi: 10.1186/s13104-020-4936-2.

3.

Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia.

Domenech C, Pastore A, Altamura AC, Bernasconi C, Corral R, Elkis H, Evans J, Malla A, Margari F, Krebs MO, Nordstroem AL, Zink M, Haro JM.

Neuropsychiatr Dis Treat. 2019 Dec 20;15:3475-3486. doi: 10.2147/NDT.S218578. eCollection 2019.

4.

Predicting the individual risk of psychosis conversion in at-risk mental state (ARMS): a multivariate model reveals the influence of nonpsychotic prodromal symptoms.

Bourgin J, Duchesnay E, Magaud E, Gaillard R, Kazes M, Krebs MO.

Eur Child Adolesc Psychiatry. 2019 Dec 23. doi: 10.1007/s00787-019-01461-y. [Epub ahead of print]

PMID:
31872289
5.

Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis.

Modinos G, Kempton MJ, Tognin S, Calem M, Porffy L, Antoniades M, Mason A, Azis M, Allen P, Nelson B, McGorry P, Pantelis C, Riecher-Rössler A, Borgwardt S, Bressan R, Barrantes-Vidal N, Krebs MO, Nordentoft M, Glenthøj B, Ruhrmann S, Sachs G, Rutten B, van Os J, de Haan L, Velthorst E, van der Gaag M, Valmaggia LR, McGuire P; EU-GEI High Risk Study Group.

JAMA Psychiatry. 2019 Nov 13. doi: 10.1001/jamapsychiatry.2019.3501. [Epub ahead of print]

6.

European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP).

Fusar-Poli P, Bauer M, Borgwardt S, Bechdolf A, Correll CU, Do KQ, Domschke K, Galderisi S, Kessing LV, Koutsouleris N, Krebs MO, Lennox B, McGuire P, Meyer-Lindenberg A, Millan MJ, Nieman D, Pfennig A, Sand M, Whenert A, van Amelsvoort T, Arango C.

Eur Neuropsychopharmacol. 2019 Dec;29(12):1301-1311. doi: 10.1016/j.euroneuro.2019.09.006. Epub 2019 Oct 9. Review.

7.

"A circle and a triangle dancing together": Alteration of social cognition in schizophrenia compared to autism spectrum disorders.

Martinez G, Mosconi E, Daban-Huard C, Parellada M, Fananas L, Gaillard R, Fatjo-Vilas M, Krebs MO, Amado I.

Schizophr Res. 2019 Aug;210:94-100. doi: 10.1016/j.schres.2019.05.043. Epub 2019 Jun 7.

PMID:
31178362
8.

Psychiatric symptoms and quality of life in older adults with schizophrenia spectrum disorder: results from a multicenter study.

Hoertel N, Rotenberg L, Blanco C, Pascal de Raykeer R, Hanon C, Kaladjian A, Limosin F; CSA Study Group.

Eur Arch Psychiatry Clin Neurosci. 2019 May 27. doi: 10.1007/s00406-019-01026-9. [Epub ahead of print]

PMID:
31134378
9.

Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.

Freitas R, Dos Santos B, Altamura C, Bernasconi C, Corral R, Evans J, Malla A, Krebs MO, Nordstroem AL, Zink M, Haro JM, Elkis H.

Psychiatry Res. 2019 Jun;276:210-217. doi: 10.1016/j.psychres.2019.05.002. Epub 2019 May 8.

PMID:
31108345
10.

Impaired attentional modulation of sensorimotor control and cortical excitability in schizophrenia.

Carment L, Dupin L, Guedj L, Térémetz M, Krebs MO, Cuenca M, Maier MA, Amado I, Lindberg PG.

Brain. 2019 Jul 1;142(7):2149-2164. doi: 10.1093/brain/awz127.

11.

Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study.

Menghini-Müller S, Studerus E, Ittig S, Heitz U, Egloff L, Andreou C, Valmaggia LR, Kempton MJ, van der Gaag M, de Haan L, Nelson B, Barrantes-Vidal N, Nordentoft M, Ruhrmann S, Sachs G, Rutten BP, Os JV, Riecher-Rössler A; EU-GEI High Risk Study Group, McGuire P, Valmaggia LR, Kempton MJ, Calem M, Tognin S, Modinos G, de Haan L, van der Gaag M, Velthorst E, Kraan TC, van Dam DS, Burger N, Nelson B, McGorry P, Amminger GP, Pantelis C, Politis A, Goodall J, Riecher-Rössler A, Borgwardt S, Rapp C, Ittig S, Studerus E, Smieskova R, Bressan R, Gadelha A, Brietzke E, Asevedo G, Asevedo E, Zugman A, Barrantes-Vidal N, Domínguez-Martínez T, Racioppi A, Cristóbal-Narváez P, Kwapil TR, Monsonet M, Kazes M, Daban C, Bourgin J, Gay O, Mam-Lam-Fook C, Krebs MO, Nordholm D, Randers L, Krakauer K, Glenthøj L, Glenthøj B, Nordentoft M, Ruhrmann S, Gebhard D, Arnhold J, Klosterkötter J, Sachs G, Lasser I, Winklbaur B, Delespaul PA, Rutten BP, van Os J.

Eur Psychiatry. 2019 Jun;59:52-59. doi: 10.1016/j.eurpsy.2019.04.007. Epub 2019 May 7.

PMID:
31075522
12.

Perinatal Exposure to Environmental Endocrine Disruptors in the Emergence of Neurodevelopmental Psychiatric Diseases: A Systematic Review.

Rivollier F, Krebs MO, Kebir O.

Int J Environ Res Public Health. 2019 Apr 12;16(8). pii: E1318. doi: 10.3390/ijerph16081318.

13.

[Cerebral maturation in adolescence and cannabis use].

Krebs MO, M Jay T.

Rev Prat. 2018 Jun;68(6):675. French. No abstract available.

PMID:
30869263
14.

Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders.

Krebs MO, Kebir O, Jay TM.

Eur J Pain. 2019 Aug;23(7):1225-1233. doi: 10.1002/ejp.1377. Epub 2019 Mar 19. Review.

PMID:
30793421
15.

Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming.

Bellon A, Wegener A, Lescallette AR, Valente M, Yang SK, Gardette R, Matricon J, Mouaffak F, Watts P, Vimeux L, Yun JK, Kawasawa YI, Clawson GA, Blandin E, Chaumette B, Jay TM, Krebs MO, Feuillet V, Hosmalin A.

Front Mol Neurosci. 2018 Sep 19;11:323. doi: 10.3389/fnmol.2018.00323. eCollection 2018.

16.

Predictive Modulation of Corticospinal Excitability and Implicit Encoding of Movement Probability in Schizophrenia.

Dupin L, Carment L, Guedj L, Cuenca M, Krebs MO, Maier MA, Amado I, Lindberg PG.

Schizophr Bull. 2019 Oct 24;45(6):1358-1366. doi: 10.1093/schbul/sby186.

PMID:
30561714
17.

Burnout in medical students before residency: A systematic review and meta-analysis.

Frajerman A, Morvan Y, Krebs MO, Gorwood P, Chaumette B.

Eur Psychiatry. 2019 Jan;55:36-42. doi: 10.1016/j.eurpsy.2018.08.006. Epub 2018 Oct 29.

PMID:
30384110
18.

One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.

Fefeu M, De Maricourt P, Cachia A, Hoertel N, Vacheron MN, Wehbe E, Rieu C, Olie JP, Krebs MO, Gaillard R, Plaze M.

Psychiatry Res. 2018 Dec;270:205-210. doi: 10.1016/j.psychres.2018.09.041. Epub 2018 Sep 19.

PMID:
30267984
19.

Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Soler J, Fañanás L, Parellada M, Krebs MO, Rouleau GA, Fatjó-Vilas M.

J Psychiatry Neurosci. 2018 Jul;43(4):223-244.

20.

High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia.

Dollfus S, Jaafari N, Guillin O, Trojak B, Plaze M, Saba G, Nauczyciel C, Montagne Larmurier A, Chastan N, Meille V, Krebs MO, Ayache SS, Lefaucheur JP, Razafimandimby A, Leroux E, Morello R, Marie Batail J, Brazo P, Lafay N, Wassouf I, Harika-Germaneau G, Guillevin R, Guillevin C, Gerardin E, Rotharmel M, Crépon B, Gaillard R, Delmas C, Fouldrin G, Laurent G, Nathou C, Etard O.

Schizophr Bull. 2018 Apr 6;44(3):505-514. doi: 10.1093/schbul/sbx127.

Supplemental Content

Loading ...
Support Center